• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

美罗培南-巴硼巴坦作为头孢他啶-阿维巴坦、头孢地尔耐药的产KPC-3（KPC-3的D179Y变体）的ST-512的挽救治疗药物。

Meropenem-Vaborbactam as Salvage Therapy for Ceftazidime-Avibactam-, Cefiderocol-Resistant ST-512 -Producing KPC-31, a D179Y Variant of KPC-3.

作者信息

Tiseo Giusy, Falcone Marco, Leonildi Alessandro, Giordano Cesira, Barnini Simona, Arcari Gabriele, Carattoli Alessandra, Menichetti Francesco

机构信息

Infectious Diseases Clinic, Department of Clinical and Experimental Medicine, Azienda Universitaria Ospedaliera Pisana, University of Pisa, Pisa, Italy.

Microbiology Unit, Azienda Universitaria Ospedaliera Pisana, Pisa, Italy.

出版信息

Open Forum Infect Dis. 2021 Mar 20;8(6):ofab141. doi: 10.1093/ofid/ofab141. eCollection 2021 Jun.

DOI:10.1093/ofid/ofab141
PMID:34189161
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8233566/
Abstract

A 68-year-old man had recurrent bacteremia by carbapenemase (KPC)-producing resistant to ceftazidime-avibactam and cefiderocol. The sequencing of a target region showed that it harbored a KPC-3 variant enzyme (D179Y; KPC-31), which confers resistance to ceftazidime-avibactam and restores meropenem susceptibility. The patient was successfully treated with meropenem-vaborbactam.

摘要

一名68岁男性因产碳青霉烯酶（KPC）而反复发生菌血症，对头孢他啶-阿维巴坦和头孢地尔耐药。靶区域测序显示其携带一种KPC-3变异酶（D179Y；KPC-31），该酶赋予对头孢他啶-阿维巴坦的耐药性并恢复美罗培南敏感性。该患者接受美罗培南-巴波巴坦治疗成功。

相似文献

1
Meropenem-Vaborbactam as Salvage Therapy for Ceftazidime-Avibactam-, Cefiderocol-Resistant ST-512 -Producing KPC-31, a D179Y Variant of KPC-3.美罗培南-巴硼巴坦作为头孢他啶-阿维巴坦、头孢地尔耐药的产KPC-3（KPC-3的D179Y变体）的ST-512的挽救治疗药物。
Open Forum Infect Dis. 2021 Mar 20;8(6):ofab141. doi: 10.1093/ofid/ofab141. eCollection 2021 Jun.
2
Meropenem/vaborbactam activity : a new option for carbapenemase (KPC)-producing treatment.美罗培南/法硼巴坦活性：产碳青霉烯酶（KPC）治疗的新选择。
Future Microbiol. 2021 Nov;16:1261-1266. doi: 10.2217/fmb-2021-0007. Epub 2021 Oct 22.
3
Bloodstream infection caused by KPC-producing Klebsiella pneumoniae resistant to ceftazidime/avibactam: epidemiology and genomic characterization.产碳青霉烯酶肺炎克雷伯菌引起的对头孢他啶/阿维巴坦耐药的血流感染：流行病学与基因组特征。
Clin Microbiol Infect. 2020 Apr;26(4):516.e1-516.e4. doi: 10.1016/j.cmi.2019.11.011. Epub 2019 Nov 16.
4
In vivo development of resistance to novel β-lactam/β-lactamase inhibitor combinations in KPC-producing Klebsiella pneumoniae infections: a case series.产 KPC 肺炎克雷伯菌感染中新型β-内酰胺/β-内酰胺酶抑制剂合剂耐药性的体内发展：病例系列。
Eur J Clin Microbiol Infect Dis. 2024 Dec;43(12):2407-2417. doi: 10.1007/s10096-024-04958-w. Epub 2024 Oct 10.
5
Review of Ceftazidime-Avibactam, Meropenem-Vaborbactam, and Imipenem/Cilastatin-Relebactam to Target Carbapenemase-Producing Enterobacterales.头孢他啶-阿维巴坦、美罗培南-瓦博巴坦和亚胺培南/西司他丁-瑞来巴坦用于治疗产碳青霉烯酶肠杆菌科细菌的综述。
J Pharm Technol. 2020 Oct;36(5):202-210. doi: 10.1177/8755122520934726. Epub 2020 Jun 17.
6
Potency of Vaborbactam Is Less Affected than That of Avibactam in Strains Producing KPC-2 Mutations That Confer Resistance to Ceftazidime-Avibactam.产生赋予对头孢他啶-阿维巴坦耐药性的 KPC-2 突变的菌株中，沃博巴坦的效力比阿维巴坦的效力受影响更小。
Antimicrob Agents Chemother. 2020 Mar 24;64(4). doi: 10.1128/AAC.01936-19.
7
Effects of KPC Variant and Porin Genotype on the Activity of Meropenem-Vaborbactam against Carbapenem-Resistant .KPC 变体和孔蛋白基因型对美罗培南-沃班坦对碳青霉烯类耐药 的活性的影响。
Antimicrob Agents Chemother. 2019 Feb 26;63(3). doi: 10.1128/AAC.02048-18. Print 2019 Mar.
8
Mutations in differentially impact synergy of meropenem/vaborbactam and ceftazidime/avibactam in combination with other antibiotics against KPC-producing .中的突变对美罗培南/巴硼巴坦以及头孢他啶/阿维巴坦与其他抗生素联合使用针对产KPC的协同作用有不同影响。
JAC Antimicrob Resist. 2023 Oct 26;5(5):dlad113. doi: 10.1093/jacamr/dlad113. eCollection 2023 Oct.
9
Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections.耐碳青霉烯类肺炎克雷伯菌感染治疗期间因质粒介导的突变导致头孢他啶-阿维巴坦耐药的出现
Antimicrob Agents Chemother. 2017 Feb 23;61(3). doi: 10.1128/AAC.02097-16. Print 2017 Mar.
10
Outbreak of Klebsiella pneumoniae ST11 Resistant To Ceftazidime-Avibactam Producing KPC-31 and the Novel Variant KPC-115 during COVID-19 Pandemic in Argentina.在 COVID-19 大流行期间，阿根廷出现了对头孢他啶-阿维巴坦耐药的肺炎克雷伯菌 ST11，同时携带 KPC-31 和新型变体 KPC-115。
Microbiol Spectr. 2022 Dec 21;10(6):e0373322. doi: 10.1128/spectrum.03733-22. Epub 2022 Nov 29.

引用本文的文献

1
Mechanisms of Cefiderocol Resistance in Carbapenemase-Producing Enterobacterales: Insights from Comparative Genomics.产碳青霉烯酶肠杆菌科细菌对头孢地尔耐药的机制：比较基因组学研究见解
Antibiotics (Basel). 2025 Jul 12;14(7):703. doi: 10.3390/antibiotics14070703.
2
Diverse modes of ceftazidime/avibactam resistance acquisition in carbapenem-resistant Klebsiella pneumoniae and Pseudomonas aeruginosa from a Chinese intensive care unit.来自中国重症监护病房的耐碳青霉烯类肺炎克雷伯菌和铜绿假单胞菌中获得头孢他啶/阿维巴坦耐药性的多种模式
Ann Clin Microbiol Antimicrob. 2025 May 30;24(1):35. doi: 10.1186/s12941-025-00800-z.
3
Cefiderocol-Resistant Bacteremia Following WATCHMAN Implantation: A Case Report and Review of the Literature.WATCHMAN植入术后出现对头孢地尔耐药的菌血症：一例病例报告及文献综述
Case Rep Infect Dis. 2025 May 20;2025:5221364. doi: 10.1155/crdi/5221364. eCollection 2025.
4
Meropenem-Vaborbactam for Treatment of Carbapenem-Resistant Enterobacterales: A Narrative Review of Clinical Practice Evidence.美罗培南-巴坦治疗耐碳青霉烯类肠杆菌科细菌感染：临床实践证据的叙述性综述
Infect Dis Ther. 2025 May;14(5):973-989. doi: 10.1007/s40121-025-01146-x. Epub 2025 Apr 12.
5
In vitro mimicry of in vivo KPC mutations by ceftazidime-avibactam: phenotypes, mechanisms, genetic structure and kinetics of enzymatic hydrolysis.头孢他啶-阿维巴坦体外模拟体内 KPC 突变：表型、机制、酶水解的遗传结构和动力学。
Emerg Microbes Infect. 2024 Dec;13(1):2356146. doi: 10.1080/22221751.2024.2356146. Epub 2024 Jun 4.
6
Real-world experience with meropenem/vaborbactam for the treatment of infections caused by ESBL-producing Enterobacterales and carbapenem-resistant Klebsiella pneumoniae.美罗培南/巴罗沙班治疗产超广谱β-内酰胺酶肠杆菌科细菌感染及耐碳青霉烯类肺炎克雷伯菌感染的真实世界经验。
Eur J Clin Microbiol Infect Dis. 2024 Feb 20. doi: 10.1007/s10096-024-04758-2.
7
Meropenem/Vaborbactam: β-Lactam/β-Lactamase Inhibitor Combination, the Future in Eradicating Multidrug Resistance.美罗培南/瓦博巴坦：β-内酰胺/β-内酰胺酶抑制剂组合，根除多重耐药性的未来。
Antibiotics (Basel). 2023 Nov 10;12(11):1612. doi: 10.3390/antibiotics12111612.
8
carbapenemase variants: the new threat to global public health.碳青霉烯酶变体：对全球公共健康的新威胁。
Clin Microbiol Rev. 2023 Dec 20;36(4):e0000823. doi: 10.1128/cmr.00008-23. Epub 2023 Nov 8.
9
Emergence of KPC-134, a KPC-2 variant associated with ceftazidime-avibactam resistance in a ST11 clinical strain.KPC-134的出现，一种与ST11临床菌株中头孢他啶-阿维巴坦耐药相关的KPC-2变体。
Microbiol Spectr. 2023 Sep 29;11(5):e0072523. doi: 10.1128/spectrum.00725-23.
10
A Whole-Genome Sequencing-Based Approach for the Characterization of Co-Producing KPC and OXA-48-like Carbapenemases Circulating in Sardinia, Italy.一种基于全基因组测序的方法，用于鉴定在意大利撒丁岛传播的同时产生KPC和OXA-48样碳青霉烯酶的菌株特征。
Microorganisms. 2023 Sep 20;11(9):2354. doi: 10.3390/microorganisms11092354.

本文引用的文献

1
Pragmatic options for dose optimization of ceftazidime/avibactam with aztreonam in complex patients.在复杂患者中对头孢他啶/阿维巴坦与氨曲南进行剂量优化的实用方案。
J Antimicrob Chemother. 2021 Mar 12;76(4):1025-1031. doi: 10.1093/jac/dkaa549.
2
Ceftazidime/avibactam in the era of carbapenemase-producing Klebsiella pneumoniae: experience from a national registry study.产碳青霉烯酶肺炎克雷伯菌时代的头孢他啶/阿维巴坦：来自国家登记研究的经验。
J Antimicrob Chemother. 2021 Feb 11;76(3):775-783. doi: 10.1093/jac/dkaa503.
3
New β-Lactam-β-Lactamase Inhibitor Combinations.新型β-内酰胺类-β-内酰胺酶抑制剂复方制剂
Clin Microbiol Rev. 2020 Nov 11;34(1). doi: 10.1128/CMR.00115-20. Print 2020 Dec 16.
4
Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa).美国传染病学会关于产超广谱β-内酰胺酶肠杆菌科（ESBL-E）、耐碳青霉烯肠杆菌科（CRE）和治疗困难的耐药铜绿假单胞菌（DTR-P. aeruginosa）的治疗指南。
Clin Infect Dis. 2021 Apr 8;72(7):e169-e183. doi: 10.1093/cid/ciaa1478.
5
Cefiderocol as Rescue Therapy for Acinetobacter baumannii and Other Carbapenem-resistant Gram-negative Infections in Intensive Care Unit Patients.头孢地尔在 ICU 患者治疗鲍曼不动杆菌和其他碳青霉烯类耐药革兰氏阴性菌感染中的应用。
Clin Infect Dis. 2021 Jun 1;72(11):2021-2024. doi: 10.1093/cid/ciaa1410.
6
Ceftazidime-Avibactam Combination Therapy Compared to Ceftazidime-Avibactam Monotherapy for the Treatment of Severe Infections Due to Carbapenem-Resistant Pathogens: A Systematic Review and Network Meta-Analysis.头孢他啶-阿维巴坦联合治疗与头孢他啶-阿维巴坦单药治疗对碳青霉烯类耐药病原体所致严重感染的疗效比较：一项系统评价和网状Meta分析
Antibiotics (Basel). 2020 Jul 7;9(7):388. doi: 10.3390/antibiotics9070388.
7
Efficacy of Ceftazidime-avibactam Plus Aztreonam in Patients With Bloodstream Infections Caused by Metallo-β-lactamase-Producing Enterobacterales.头孢他啶-阿维巴坦联合氨曲南治疗产金属β-内酰胺酶肠杆菌科血流感染的疗效。
Clin Infect Dis. 2021 Jun 1;72(11):1871-1878. doi: 10.1093/cid/ciaa586.
8
Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia.头孢地尔罗对多重耐药肠杆菌科、鲍曼不动杆菌、铜绿假单胞菌和嗜麦芽窄食单胞菌高危克隆的活性。
J Antimicrob Chemother. 2020 Jul 1;75(7):1840-1849. doi: 10.1093/jac/dkaa117.
9
Evaluation of five carbapenemase detection assays for Enterobacteriaceae harbouring blaKPC variants associated with ceftazidime/avibactam resistance.对携带与头孢他啶/阿维巴坦耐药相关的blaKPC变体的肠杆菌科细菌进行五种碳青霉烯酶检测方法的评估。
J Antimicrob Chemother. 2020 Jul 1;75(7):2010-2013. doi: 10.1093/jac/dkaa079.
10
Clinical Features and Outcomes of Bloodstream Infections Caused by New Delhi Metallo-β-Lactamase-Producing During a Regional Outbreak.新德里金属β-内酰胺酶产生菌引起的血流感染在区域暴发期间的临床特征及转归
Open Forum Infect Dis. 2020 Jan 21;7(2):ofaa011. doi: 10.1093/ofid/ofaa011. eCollection 2020 Feb.